Rigel Pharmaceuticals (RIGL) Corporate presentation summary

Transformational growth strategy

• Expanded from one to three commercial products between 2020 and 2025, with a focus on hematology and oncology.

• Profitable since Q3 2024, with cash increasing from $49.1M (6/30/24) to $155M (12/31/25).

• Future growth targets include in-licensing/M&A and advancing a robust development pipeline, notably R289.

Commercial performance and portfolio

• Q1 2026 net product sales reached $54.9M, up 26% from Q1 2025.

• TAVALISSE led with $37.3M (31% YoY growth), GAVRETO $9.6M (7%), and REZLIDHIA $8.0M (31%).

• Commercial portfolio addresses chronic immune thrombocytopenia, relapsed/refractory AML with IDH1 mutation, and RET fusion-positive cancers.

• Significant U.S. and global market access, with collaborations in Europe, Asia, and Latin America.

Pipeline and clinical development

• R289 (IRAK1/4 inhibitor) in Phase 1b for relapsed/refractory lower-risk MDS, showing promising safety and efficacy.

• R289 granted Fast Track and Orphan Drug designations; 33% of evaluable transfusion-dependent patients achieved RBC transfusion independence at ≥500mg QD.

• Olutasidenib being advanced in AML, MDS, and glioma through strategic alliances and precision medicine trials.